Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $253 | $299 | $314 | $354 | $389 |
| Gross Profit | $168 | $198 | $203 | $229 | $249 |
| Operating Income | $2 | $8 | $6 | $6 | $39 |
| Net Income | -$17 | -$15 | -$19 | -$31 | -$13 |
Over the past five years, ARTIVION’s financial data shows a steady increase in revenue and gross profit, reflecting a potentially robust demand for its products in a competitive market. Revenues grew from roughly USD 253 million in 2020 to nearly USD 389 million in 2024, with notable increases between 2020 and 2021 (an 18% jump) and continued momentum in subsequent years. Gross profit similarly expanded from USD 168 million to almost USD 249 million over the period, indicating that the company has maintained its ability to generate healthy margins from its core operations. However, it is worth noting that operating income remained relatively modest until 2024, when it surged from around USD 5.7 million in 2023 to nearly USD 38.9 million in 2024—a more than sixfold increase that signals a meaningful operational efficiency or cost-control initiative may have taken effect. Despite these positive trends in top-line and operating performance, net income has consistently been in the red over the analyzed period, though there was some improvement in 2024. The net loss narrowed from over USD 30 million in 2023 to about USD 13.4 million in 2024, suggesting that while the company continues to face challenges at the bottom line, its operational improvements are beginning to translate into a less severe net loss. In the context of the medical device and surgical implant industry, which is often characterized by high regulatory standards and competitive pressures, these trends imply that ARTIVION is working to balance revenue growth with efficiency gains. Overall, the company’s upward trajectory in revenue and operating income, coupled with a narrowing net loss, indicates improving financial health and a gradually more sustainable business model, though persistent losses warrant close monitoring.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.